Blueprint Medicines Corporation
General ticker "BPMC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $6.0B (TTM average)
Blueprint Medicines Corporation follows the US Stock Market performance with the rate: 35.4%.
Estimated limits based on current volatility of 0.2%: low 128.04$, high 128.35$
Factors to consider:
- US accounted for 82.9% of revenue in the fiscal year ended 2024-12-31
- Current price 16.4% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [51.49$, 110.06$]
- 2025-12-31 to 2026-12-31 estimated range: [32.25$, 74.07$]
Financial Metrics affecting the BPMC estimates:
- Negative: Non-GAAP EPS, $ of -3.80 <= 0.05
- Negative: Operating cash flow per share per price, % of -3.16 <= 1.99
- Positive: -0.89 < Investing cash flow per share, $ of -0.76
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: 21.94 < Shareholder equity ratio, % of 25.31 <= 42.99
Short-term BPMC quotes
Long-term BPMC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $189.27MM | $249.38MM | $508.82MM |
| Operating Expenses | $741.55MM | $735.66MM | $720.87MM |
| Operating Income | $-552.28MM | $-486.28MM | $-212.04MM |
| Non-Operating Income | $0.00MM | $-19.74MM | $146.18MM |
| Interest Expense | $16.77MM | $0.00MM | $68.81MM |
| R&D Expense | $477.42MM | $427.72MM | $341.43MM |
| Income(Loss) | $-552.28MM | $-506.02MM | $-65.86MM |
| Taxes | $5.24MM | $0.97MM | $1.23MM |
| Profit(Loss)* | $-557.52MM | $-506.98MM | $-67.09MM |
| Stockholders Equity | $514.68MM | $130.61MM | $298.67MM |
| Inventory | $29.70MM | $21.22MM | $13.61MM |
| Assets | $1,349.90MM | $1,049.25MM | $1,179.81MM |
| Operating Cash Flow | $-502.28MM | $-436.85MM | $-192.59MM |
| Capital expenditure | $8.92MM | $16.06MM | $4.63MM |
| Investing Cash Flow | $-149.54MM | $274.04MM | $-47.50MM |
| Financing Cash Flow | $561.81MM | $119.22MM | $273.11MM |
| Earnings Per Share** | $-9.35 | $-8.37 | $-1.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.